Reference : Percutaneous left atrial appendage closure: procedural techniques and outcomes.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/227157
Percutaneous left atrial appendage closure: procedural techniques and outcomes.
English
Saw, Jacqueline [> >]
LEMPEREUR, Mathieu mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Cardiologie interventionnelle >]
2014
JACC. Cardiovascular Interventions
7
11
1205-20
Yes (verified by ORBi)
International
19368798
18767605
United States
[en] Atrial Appendage/physiopathology ; Atrial Fibrillation/complications/diagnosis/physiopathology/therapy ; Cardiac Catheterization/adverse effects/instrumentation/methods ; Equipment Design ; Hemorrhage/etiology ; Humans ; Risk Assessment ; Risk Factors ; Stroke/etiology/prevention & control ; Time Factors ; Treatment Outcome ; Amplatzer Cardiac Plug ; Amulet ; Lariat ; WATCHMAN ; left atrial appendage closure
[en] Percutaneous left atrial appendage closure technology for stroke prevention in patients with atrial fibrillation has significantly advanced in the past 2 decades. Several devices are under clinical investigation, and a few have already received Conformite Europeene (CE)-mark approval and are available in many countries. The WATCHMAN device (Boston Scientific, Natick, Massachusetts) has the most supportive data and is under evaluation by the U.S. Food and Drug Administration for warfarin-eligible patients. The Amplatzer Cardiac Plug (St. Jude Medical, Plymouth, Minnesota) has a large real-world experience over the past 5 years, and a randomized trial comparing Amplatzer Cardiac Plug with the WATCHMAN device is anticipated in the near future. The Lariat procedure (SentreHEART Inc., Redwood City, California) has also gained interest lately, but early studies were concerning for high rates of serious pericardial effusion and major bleeding. The current real-world experience predominantly involves patients who are not long-term anticoagulation candidates or who are perceived to have high bleeding risks. This pattern of practice is expected to change when the U.S. Food and Drug Administration approves the WATCHMAN device for warfarin-eligible patients. This paper reviews in depth the procedural techniques, safety, and outcomes of the current leading devices.
http://hdl.handle.net/2268/227157
10.1016/j.jcin.2014.05.026
Copyright (c) 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
JACC Intv-Saw-2014-LAA review.pdfPublisher postprint3.57 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.